Status:
UNKNOWN
Effect of Preoperative Curcumin in Breast Cancer Patients
Lead Sponsor:
University of Malaya
Conditions:
Breast Cancer
Eligibility:
FEMALE
Phase:
NA
Brief Summary
Effect of curcumin on modulation of immune and inflammatory parameters in pre-operative patients
Detailed Description
Patients diagnosed with breast cancer will be supplemented with either curcumin or placebo for a minimum period of 2 weeks and may be extended up to 4 weeks prior to their surgery.
Eligibility Criteria
Inclusion
- Patients with operable breast cancer
- Life expectancy of at least 3 months
- Adequate organ function
- No allergy to curcumin
- Provides consent to participate in trial and adhere to the study protocol
Exclusion
- Receiving concomitant radiotherapy, hormonal, immune therapy or other investigational drugs
- Uncontrolled concurrent illness
- Patient of anti platelet medications
- Pregnant / breast feeding
- Patients who are unable or unwilling to take curcumin, herbal remedies, or non-prescription medications
- Patients with bleeding tendency, bleeding disorders and abnormal bleeding/clotting profile
Key Trial Info
Start Date :
June 18 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03847623
Start Date
June 18 2017
End Date
December 31 2020
Last Update
March 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Malaya Medical Center
Kuala Lumpur, Malaysia